← Oncology Approval Tracker

FDA DECISION ·

Brukinsa tablets

zanubrutinib · BeOne Medicines USA

Accelerated approvalNew formulationMantle cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

A 160 mg tablet formulation for adults with mantle cell lymphoma after at least one prior therapy.

LAMPGEN ANALYSIS

Why it matters

The tablet presents the existing later-line mantle cell indication under a formulation-specific accelerated approval.

What research teams should watch

Confirm prior treatment and distinguish the scored tablet’s strength from the earlier 80 mg capsule.

PRIMARY RECORDS

Sources